Government ❯ Politics ❯ Health Policy

Drug Regulation

FDA Leadership FDA Fentanilo Contaminado FDA Actions Psychedelic Treatments Medicare Negotiations Prescription Drugs FDA Commissioner Amyl Nitrite Cost of Medications Consumer Protection Advertising Policies COVID-19 Vaccines Political Influence FDA Approval Drug Safety Pharmaceutical Industry Relations Mifepristone Safety Review Medicare Coverage Access to Healthcare Lachgas and K.-o.-Tropfen Patient Safety Price Transparency Psychedelics Research Controversial Practices Psychedelic Research Funding FDA Decisions Psychedelic Therapies Fentanyl Crisis Kratom

RFK Jr. Walks Off Tampa Event After Question on $1 Million Kratom Donation

Reporters pressed the health secretary about a major contribution from kratom-maker Botanic Tonics to his PAC and a dropped Justice Department case, prompting a Senate Finance Committee inquiry.

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

RFK Jr. To Announce New HHS Plan To Cut U.S. Drug Prices Today

HHS Orders FDA Review of Mifepristone Amid Debate Over Flawed Safety Study